BioNTech SE (BNTX)
NASDAQ: BNTX
· Real-Time Price · USD
102.09
-0.57 (-0.56%)
At close: Sep 09, 2025, 3:59 PM
103.57
1.45%
After-hours: Sep 09, 2025, 07:53 PM EDT
-0.56% (1D)
| Bid | 101.58 |
| Market Cap | 24.54B |
| Revenue (ttm) | 2.88B |
| Net Income (ttm) | -347.44M |
| EPS (ttm) | -1.66 |
| PE Ratio (ttm) | -61.5 |
| Forward PE | -24.38 |
| Analyst | Buy |
| Ask | 107.6 |
| Volume | 904,751 |
| Avg. Volume (20D) | 758,737 |
| Open | 103.82 |
| Previous Close | 102.66 |
| Day's Range | 102.03 - 104.40 |
| 52-Week Range | 81.20 - 131.49 |
| Beta | 1.40 |
About BNTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BNTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BNTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
BioNTech SE is scheduled to release its earnings on
Nov 3, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 days ago
-8.71%
BioNTech shares are trading lower. The company and...
Unlock content with
Pro Subscription
5 days ago
+8.66%
BioNTech shares are trading higher after the company announced the pivotal Phase 3 trial which DualityBio is conducting in China to evaluate trastuzumab pamirtecan versus trastuzumab emtansine in patients with HER2-positive unresectable or metastatic breast cancer who have previously received trastuzumab and a taxane-based chemotherapy met its primary endpoint.
